Nephro-Urology Monthly

Published by: Kowsar

Phosphate Metabolism Modulation in Chronic Kidney Disease: When, How and to What Extent?

Antonio Bellasi 1 , 2 , * and Biagio Raffaele Di Iorio 3
Authors Information
1 Division of Nephrology, Sant’ Anna Hospital, Como, Italy
2 Department of Health Sciences, University of Milan, Italy
3 Division of Nephrology, A. Landolfi Hospital, Solofra, Italy
Article information
  • Nephro-Urology Monthly: May 01, 2014, 6 (3); e18379
  • Published Online: April 29, 2014
  • Article Type: Editorial
  • Received: February 23, 2014
  • Revised: March 9, 2014
  • Accepted: April 14, 2014
  • DOI: 10.5812/numonthly.18379

To Cite: Bellasi A, Raffaele Di Iorio B. Phosphate Metabolism Modulation in Chronic Kidney Disease: When, How and to What Extent?, Nephro-Urol Mon. 2014 ; 6(3):e18379. doi: 10.5812/numonthly.18379.

Copyright © 2014, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Bellasi A, Cozzolino M, Adragao T, Di Iorio B, Russo D. Phosphate binders in moderate chronic kidney disease: where do we stand? J Nephrol. 2013; 26(6): 993-1000[DOI][PubMed]
  • 2. Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolo P, Malmusi G, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol. 2011; 6(4): 883-91[DOI][PubMed]
  • 3. Bellasi A, Galassi A, Cozzolino M, Di Iorio B. The evolving world of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD). EMJ Neph. 2013; 1: 20-31
  • 4. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2009; 20(1): 164-71[DOI][PubMed]
  • 5. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79(12): 1370-8[DOI][PubMed]
  • 6. Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007; 22(4): 1171-6[DOI][PubMed]
  • 7. Dominguez JR, Shlipak MG, Whooley MA, Ix JH. Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol. 2013; 24(4): 647-54[DOI][PubMed]
  • 8. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121(11): 4393-408[DOI][PubMed]
  • 9. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012; 23(8): 1407-15[DOI][PubMed]
  • 10. Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol. 2013; 24(5): 842-52[DOI][PubMed]
  • 11. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis. 2012; 59(2): 177-85[DOI][PubMed]
  • 12. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, Martinez-Moreno JM, Ramirez AP, Pineda C, et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol. 2012; 23(7): 1190-7[DOI][PubMed]
  • 13. Di Iorio B, Bellasi A, Russo D, Independent Study Investigators . Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012; 7(3): 487-93[DOI][PubMed]
  • 14. Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013; 62(4): 771-8[DOI][PubMed]
  • 15. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71(5): 438-41[DOI][PubMed]
  • 16. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. The Lancet. 2013; 382(9900): 1268-77
  • 17. Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113)-130[DOI][PubMed]
  • 18. Taylor MJ, Elgazzar HA, Chaplin S, Goldsmith D, Molony DA. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin. 2008; 24(2): 601-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments